Pyramid Analytics and Smollan forge international partnership
22.8.2023 16:06:00 EEST | Business Wire | Press release
Global retail specialists Smollan have formalised an international reseller and implementation partnership agreement with next-generation decision and business intelligence (BI) software provider Pyramid Analytics. The agreement will see Smollan, via its data and technology business, DataOrbis, expanding its current service offering to include the ability to both sell Pyramid Analytics licenses and implement Pyramid Analytics software.
“Our clients operate in incredibly competitive industries, where the ability to make the best decision, quickly is the key to strong performance. Our hunt for a BI solution that delivers superior functionality, excellent value, and next-generation capability led us to Pyramid Analytics. We migrated the majority of our DataOrbis solutions onto their software last year, and already our clients are noticing a step-change in how we can help them capitalise on the explosive amount of data they have at their fingertips,” said James Collett, Smollan’s Chief Executive: Data & Technology.
The Pyramid Analytics partnership also provides DataOrbis with a growth opportunity geared at expanding DataOrbis’ services and footprint into verticals outside of the fast-moving consumer goods (FMCG) space where they have traditionally played. This is further supported by DataOrbis and Smollan’s global footprint, which includes operations in all major gateways.
“DataOrbis has an excellent understanding of what it takes to implement a successful data strategy across an organisation, regardless of industry. We are incredibly excited to be partnering with them internationally. By leveraging their global presence throughout their client and partner networks, I believe DataOrbis, together with Pyramid Analytics, can streamline and optimise their data analytics ecosystems to prepare them for what’s next. We are thrilled to have them on board,” said Omri Kohl, Pyramid Analytics CEO.
The Pyramid Platform consistently receives top ratings among leading analyst firms that evaluate business intelligence and analytics technologies. Most recently, Pyramid earned top rankings from Gartner in the 2023 Critical Capabilities for Analytics and Business Intelligence Platforms report, including #1 for Business Analyst Use Case, #1 for Augmented Consumer Use Case, #2 for Data Scientist Use Case, and #4 for Analytics Developer Use Case.
The Pyramid Platform consolidates data preparation, business analytics, and data science into a single, integrated, self-service platform that can be accessed by all levels of data users.
“The time it takes for a decision-maker to access data can make or break a company’s competitive advantage. Pyramid Analytics reduces the amount of time it takes users across the organisation to easily find the information they need without having to request it from IT. It’s a win-win for both users and overly stretched IT departments,” said Kohl.
Implementation is key to success
As the need to unlock the power of data has accelerated, businesses are realising the benefit of having one enterprise BI platform across the organisation, ensuring a single source of truth that can be safely, securely, and ethically managed. As an early adopter, DataOrbis has invested in creating and upskilling several Pyramid Analytics’ implementation teams working out of South Africa, India, and Slovenia to assist clients in creating and implementing their own unique global views. These teams, with over 50 certified Pyramid Analytics specialists, include senior resources with expertise across industries and geographies.
“The choice of BI platform is one part of the insights puzzle. The skill and time needed to implement the software is the next piece. In our experience, most companies don’t have these two vital resources readily available. By partnering with DataOrbis we can ensure the Pyramid Analytics software is expertly implemented and used to its fullest potential—all based on global best-practises. I am excited by the opportunities the Pyramid Analytics partnership will unlock for us and our clients,” said Collett.
ABOUT
Pyramid Analytics
Pyramid Analytics is the next generation of business analytics. The award-winning Pyramid Decision Intelligence Platform empowers people with augmented, automated, and collaborative insights that simplify and guide the use of data in decision-making. Critically, the Pyramid Analytics Platform operates directly on any data, enabling governed self-service for any person, and meeting analytical needs in a no-code environment without data extraction. It combines data prep, business analytics, and data science into one frictionless platform to empower anyone with intelligent decision-making. This enables a strategic, enterprise-wide approach to business intelligence and analytics, from the simple to the sophisticated. Schedule a demo. To find out more about Pyramid Analytics contact pr@pyramidanalytics.com.
Smollan
Founded in 1931, Smollan is a global commerce business, delivering growth for retailers and brand owners across five continents. Influencing what, when, where and shoppers browse and buy across multiple touchpoints, through Sales & Merchandising, Activation & Experience, Data & Technology and Digital Commerce. Internationally recognised for our exceptional human platform of over 75 000 people and our sophisticated systems, we drive sales and create brilliant shopper experiences for some of the world’s most loved brands. We are a global business that helps retailers and brands win at the point of purchase. Contact us at www.smollan.com.
DataOrbis
A leading data and technology company, DataOrbis uses its SMART ecosystem of services, solutions and technology to expertly help companies transform into businesses driven by data. With over 50 blue-chip clients, DataOrbis currently processes over 300 sources of data across 60+ countries in multiple languages. In 2020, DataOrbis joined forces with global retail specialist Smollan, increasing its ability to scale, expand and network globally.
DataOrbis is headquartered in South Africa with offices and partners across the globe. To find out more about DataOrbis contact us here.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230822485425/en/
Contact information
Pete Vomocil
Senior Vice President, Global Marketing, Pyramid Analytics
E-Mail: pr@pyramidanalytics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Teledyne FLIR Defense Wins $17.5 Million Contract from armasuisse to Deliver Black Hornet 4 Nano-Drones for Dismounted and Vehicle-Integrated Reconnaissance2.2.2026 09:00:00 EET | Press release
Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE:TDY), announced that it has received a $17.5 million contract from armasuisse, the Swiss Federal Office of Defence Procurement, to deliver a large number of Black Hornet® 4 Personal Reconnaissance Systems, one of the world’s most advanced and widely deployed nano-drones. Black Hornet 4 was selected as an airborne dismountable Intelligence, Surveillance, and Reconnaissance (ISR) capability sensor for armasuisse’s Piranha 8x8 Armored engineering vehicle program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260201061637/en/ Teledyne FLIR Defense has won a $17.5 million contract from armasuisse, the Swiss Federal Office of Defence Procurement, to deliver a large number of Black Hornet® 4 Personal Reconnaissance Systems, one of the world’s most advanced and widely deployed nano-drones. Black Hornet 4 was selected as an airborne capability sensor for armasui
Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission2.2.2026 08:00:00 EET | Press release
Galderma (SIX: GALD) today announced that the U.S. FDA has accepted the BLA resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults. Galderma has worked closely with the U.S. FDA to implement adjustments to its manufacturing process. Galderma is committed to using its expertise and heritage in the neuromodulator space to develop next-generation aesthetic solutions that address evolving needs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260201157212/en/ “We pioneered the development of RelabotulinumtoxinA to address the growing demand for faster-acting and longer-lasting anti-wrinkle solutions. We’re excited about the potential to bring this innovative neuromodulator to the U.S., offering advanced performance and ease of use and building on our portfolio of neuromodulators that meets the full spectrum of injecto
High-end Aesthetic Brand ‘Lorient’ Gains Global Prestige at IMCAS 20261.2.2026 09:00:00 EET | Press release
Lorient, a premium aesthetic brand, announced that it has drawn global attention at the 27th IMCAS World Congress 2026 in Paris, attracting over 15,000 professionals and demonstrating its leadership in aesthetic innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131322203/en/ Lorient’s low degree of modification delivers a smooth injection experience and high biocompatibility (Image: Lorient) The highlight was a session led by Dr. Jani van Loghem, a globally revered key opinion leader known for establishing international aesthetic safety protocols. His involvement provided a prestigious validation of the technical excellence of Lorient. Alongside him, prominent Korean medical experts Dr. Won Lee and Dr. Do Young Rhee shared clinical insights that drew widespread praise from the international medical community. Central to the academic discussions was Lorient’s "safety-first" philosophy for its premium HA filler ran
Sharjah Ruler Receives Portugal’s Grand Collar of Order of Camões31.1.2026 19:27:00 EET | Press release
His Excellency Marcelo Rebelo de Sousa, President of the Portuguese Republic, awarded His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, the Grand Collar of the Order of Camões (Grande Colar da Ordem de Camões), the highest sovereign cultural order in Portugal. His Highness is the first Arab figure to receive the Order of Camões and the sixth recipient worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131119526/en/ Sharjah Ruler receives Portugal’s Grand Collar of Order of Camões (Photo: AETOSWire) The honour was conferred during a ceremony hosted by the Portuguese President at the Presidential Palace in Lisbon. The event was attended by Sheikha Bodour bint Sultan Al Qasimi, Chairperson of the Sharjah Book Authority, alongside senior officials. The ceremony recognised His Highness’s prominent global stature, as a leading figure in culture, intellectual thought and in
Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
